Pharvaris PAO discloses initial equity holdings

Rhea-AI Filing Summary

Pharvaris N.V. Principal Accounting Officer Anna Nijdam filed an initial ownership report showing her equity stake in the company. She holds 51,819 shares of common stock directly, along with a stock option on 30,000 shares of common stock at an exercise price of $20.00 per share that expires on February 5, 2031. The option vested 25% on February 5, 2022, with the remaining shares vesting in equal monthly installments thereafter. The filing also notes multiple outstanding restricted stock unit awards that settle in common shares, each vesting 25% on the first vesting date and 25% on each annual anniversary.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Nijdam Anna

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct); Common Stock — 51,819 shares (Direct)

Footnotes (2)

1. F1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -6,200 RSUs from an award granted March 3, 2026 of which 25% will vest on March 3, 2027 with the remainder vesting 25% on each annual anniversary; -6,150 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting 25% on each annual anniversary; -5,250 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting 25% on each annual anniversary; -7,500 RSUs from an award granted April 6, 2023 of which 25% vested April 6, 2024 with the remainder vesting 25% on each annual anniversary; -3,554 RSUs from an award granted April 1, 2022 of which 25% vested April 1, 2023 with the remainder vesting 25% on each annual anniversary.
2. F2. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

FAQ

What does the Pharvaris (PHVS) Form 3 filing for Anna Nijdam show?

The Form 3 shows Anna Nijdam’s initial ownership in Pharvaris common stock and equity awards, including 51,819 directly held shares and a stock option on 30,000 shares at $20.00 per share, plus several outstanding restricted stock unit awards that vest over multiple years.

How many Pharvaris (PHVS) common shares does Anna Nijdam directly own?

Anna Nijdam directly owns 51,819 shares of Pharvaris common stock. This direct stake is disclosed in the Form 3 as her non-derivative ownership, separate from her stock options and restricted stock units that may convert into additional shares in the future.

What stock option position does Anna Nijdam report in Pharvaris (PHVS)?

She reports a stock option covering 30,000 Pharvaris common shares at an exercise price of $20.00 per share, expiring February 5, 2031. Twenty-five percent vested on February 5, 2022, with the remaining shares vesting in equal monthly installments thereafter.

What restricted stock units (RSUs) are outstanding for Anna Nijdam at Pharvaris (PHVS)?

The filing lists several RSU awards granted between 2022 and 2026, each vesting 25% on an initial date and 25% on each annual anniversary. Individual grants include 6,200, 6,150, 5,250, 7,500 and 3,554 RSUs that settle in Pharvaris common shares.

Does the Pharvaris (PHVS) Form 3 indicate any recent share purchases or sales by Anna Nijdam?

The Form 3 does not report new purchases or sales; it is an initial statement of beneficial ownership. It lists her existing common stock, stock option, and RSU positions, rather than open-market transactions or recent trading activity in Pharvaris shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 02:23 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Nijdam Anna

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	51,819(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	02/05/2031	Common Stock	30,000	$20	D

Explanation of Responses:

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -6,200 RSUs from an award granted March 3, 2026 of which 25% will vest on March 3, 2027 with the remainder vesting 25% on each annual anniversary; -6,150 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting 25% on each annual anniversary; -5,250 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting 25% on each annual anniversary; -7,500 RSUs from an award granted April 6, 2023 of which 25% vested April 6, 2024 with the remainder vesting 25% on each annual anniversary; -3,554 RSUs from an award granted April 1, 2022 of which 25% vested April 1, 2023 with the remainder vesting 25% on each annual anniversary.

2. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Anna Nijdam	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)